ABO-incompatible (ABO-I) living-donor lobar lung transplantation (LDLLT) was successfully performed in a 14-year-old girl who suffered from bronchiolitis obliterans due to graft-versus-host disease following hematopoietic stem cell transplantation. In the ABO-I LDLLT procedure, the blood type O patient received a right lower lobe donated from her blood type B father and a left lower lobe donated from her blood type O mother. Desensitization therapy, using rituximab, immunosuppressants, and plasmapheresis, was implemented for 3 weeks prior to transplantation to reduce the production of anti-B antibodies in the recipient and prevent acute antibody-mediated rejection after ABO-I LDLLT.
Ischemia reperfusion injury (IRI) is a significant risk factor for primary graft dysfunction following lung transplantation. Toll-like receptor 4 (TLR4) signaling plays an important role not only in IRI but also in the development of acute and chronic allograft rejection. We investigated the therapeutic effect of Viral Inhibitory Peptide for TLR4 (VIPER), a pharmacological TLR4-inhibitory peptide, in a clinically relevant murine lung transplantation model. VIPER-treated lungs demonstrated improved function, with reduced mean airway pressure and increased compliance and inspiratory volume. The wet-to-dry weight ratio was significantly reduced, indicating decreased pulmonary edema. Inflammatory cytokines monocyte chemoattractant protein-1 (MCP-1), interferon-gamma (IFN-γ), and interleukin-6 (IL-6) were significantly decreased, with a trend toward lower levels of the fibrogenetic cytokine transforming growth factor-beta (TGF-β). Histological evaluation revealed reduced acute lung injury scores and fewer inducible nitric oxide synthase (iNOS)-positive inflammatory cells. These findings demonstrate that pharmacological inhibition of TLR4 with VIPER effectively attenuates IRI-associated inflammation and improves early graft function. Such pharmacological TLR4-targeting strategies might represent a therapeutic approach in lung transplantation.
28 May 2025 in The Journal of Heart and Lung Transplantation
Background: Pulmonary pseudoaneurysm (PPA) is a potentially lethal complication of lung resection with a high risk of recurrence after endovascular coiling. Case presentation: We report a case in which recurrent hemoptysis due to PPA after left lower lobe sleeve resection was treated by endovascular embolization of the left main pulmonary artery as a salvage treatment. The first hemoptysis was managed by endovascular coil embolization with extracorporeal membrane oxygenation, but refractory hemorrhage occurred 3 months later due to penetration of the endovascular coil into the bronchial anastomosis site. Because left completion pneumonectomy was considered too high risk, the left main pulmonary artery was palliatively embolized using an Amplatzer vascular plug (St. Jude Medical, MN, USA) to totally disrupt the left pulmonary arterial flow. Conclusions: Total embolization of the left main pulmonary artery for repeated PPA rupture may be useful as a palliative treatment in patients unable to tolerate pneumonectomy.